NCT05444153View on ClinicalTrials.gov

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 6, 2022

Primary Completion Date

October 2, 2024

Study Completion Date

August 29, 2025

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants will receive 1 tablet of oral semaglutide once daily.

DRUG

Empagliflozin

Participants will receive 1 tablet of empagliflozin once daily.

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY